Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.60% in the past week. It has experienced a 5-day net outflow of $224.35 million.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- AbbVie has made significant strides by completing the acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin, aimed at treating major depressive disorder. This acquisition could potentially enhance AbbVie’s portfolio in the mental health sector. Furthermore, AbbVie’s stock has seen positive analyst activity, with Raymond James raising its price target to $250 and Piper Sandler reiterating a Buy rating with a target of $284. Despite these positive outlooks, insider sentiment remains negative due to increased insider selling. The completion of a Phase 2 study on CLL/SLL treatment in Japan could also bolster investor confidence.
- Amgen Inc has been receiving favorable attention from analysts, with Piper Sandler reiterating a Buy rating and setting a price target of $342, suggesting a potential upside. The company’s shares are currently trading around $295, with a consensus price target of $322.59, indicating an 8.2% upside. Amgen’s recent 60% discount on its cholesterol drug, Repatha, aligns with broader industry trends towards more affordable medication pricing, potentially enhancing its market position.
- Pepsico was not mentioned in the provided text, and therefore, no recent news or updates are available for this company in the context of the given information.